Labcorp's PGDx elio® tissue complete CDx has received FDA approval as a companion diagnostic to identify advanced melanoma patients with specific BRAF mutations. This test helps clinicians determine which patients may benefit from targeted BRAF and BRAF/MEK inhibitor therapies, improving treatment options for a deadly skin cancer with low survival rates. The test is scalable for use in hospitals and labs, supporting broader access to personalized cancer care. Labcorp continues to expand its precision medicine portfolio with this approval, enhancing patient access to advanced molecular diagnostics.
Initta Technology showcased its new AI-driven retail solutions at its annual partner conference in Nanchang, emphasizing its shift from hardware supplier to AI-enabled service provider. The company highlighted its partnership with Intel, using Intel'...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on August 7, 2026. The bank purchased 9,541 ordinary shares at 281.25 per share and sold 147,431 shares between 281 and 28...
Berkshire Hathaway reported a $1.8 billion increase in operating earnings last quarter, with a significant $1.2 billion portion attributed to favorable currency exchange movements. This currency impact notably boosted the company's financial results,...
The global Travel Now Pay Later (TNPL) market, valued at $45 billion in 2024, is projected to reach $77.6 billion by 2030, growing at a 9.5% CAGR. TNPL allows travelers to book flights, hotels, and tours with flexible installment payments, boosting b...
Zentek Ltd. released a Preliminary Economic Assessment (PEA) for its Albany Graphite Project in Ontario, highlighting a $3.85 billion after-tax net present value (NPV) and a 27.4% internal rate of return (IRR). The project aims to produce ultra-high-...
